CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Biomea Fusion, Inc. (BMEA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Biomea Fusion, Inc. (BMEA)

Pharmaceutical Preparations · market cap $100M · as of 2026-07-15

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-03-15 (est.)
Phase 2
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Biomea Fusion (BMEA) is a clinical-stage pharmaceutical company with a single disclosed pipeline asset, BMF-219, currently in Phase 2 development for Type 2 Diabetes Mellitus. The company carries a ~$96M market cap against $44.7M in cash, implying roughly 11.5 months of runway and an enterprise value near $51M. Mechanism of action for BMF-219 is not disclosed in available facts.
The catalyst path
  • 2027-03-15 (est.)Phase 2 · icovamenibimp 7/10
  • 2027-06-15 (est.)Phase 2 · icovamenibimp 7/10
Pipeline
AssetPhaseIndication
BMF-219Phase 2Type 2 Diabetes Mellitus
icovamenibPhase 2Type 2 Diabetes
Price & technical context
3-month
-56.9%
6-month
-56.9%
12-month
-50.0%
52-wk range
$0.49–$2.21
vs 50-day MA
-42.5%
vs 200-day MA
-55.4%
Realized vol
96.5%
Max drawdown
-96.1%

Daily closes through 2026-11-19. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for BMEA (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.